Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Q4 2024 value amounting to $3.8 million.

  • Rocket Pharmaceuticals' Gains from Investment Securities changed N/A to $3.8 million in Q4 2024 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 30005.33%. This contributed to the annual value of $1.9 million for FY2024, which is 61538.46% up from last year.
  • As of Q4 2024, Rocket Pharmaceuticals' Gains from Investment Securities stood at $3.8 million.
  • Rocket Pharmaceuticals' 5-year Gains from Investment Securities high stood at $20.2 million for Q1 2020, and its period low was -$2.9 million during Q2 2024.
  • For the 5-year period, Rocket Pharmaceuticals' Gains from Investment Securities averaged around $7.9 million, with its median value being $7.0 million (2020).
  • Per our database at Business Quant, Rocket Pharmaceuticals' Gains from Investment Securities skyrocketed by 176656.98% in 2020 and then tumbled by 11937.46% in 2024.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Gains from Investment Securities stood at $6.4 million in 2020, then dropped by 18.67% to $5.2 million in 2021, then surged by 139.88% to $12.5 million in 2022, then rose by 18.75% to $14.9 million in 2023, then crashed by 74.78% to $3.8 million in 2024.
  • Its last three reported values are $3.8 million in Q4 2024, -$104000.0 for Q3 2024, and -$2.9 million during Q2 2024.